Vimarsana
Biggest News Aggregation in the World

Page 49 - Billy Dunn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Billy Dunn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Billy Dunn Today - Breaking & Trending Today

FDA weighs approval of a lucrative Alzheimer's drug but benefits are iffy | Nation/World - Vimarsana News

FDA weighs approval of a lucrative Alzheimer's drug but benefits are iffy | Nation/World

The Food and Drug Administration’s decision next week whether to approve the first treatment for Alzheimer’s disease highlights a deep division over the drug’s benefits as well as criticism about

If the FDA approves aducanumab, I won't prescribe it - Vimarsana News

If the FDA approves aducanumab, I won't prescribe it

I treat people with Alzheimer's disease. I don't think the FDA should approve aducanumab, Biogen's new treatment for the disease.

Alzheimer's Aducanumab Redosing Study Underway - Vimarsana News

Alzheimer's Aducanumab Redosing Study Underway

email article While the Alzheimer's field waits for the FDA's decision on the investigational treatment aducanumab, drug developer Biogen has provided details and endpoints of EMBARK, the drug's ongoing phase IIIb redosing study. Aducanumab, a monoclonal antibody that selectively binds to aggregated forms of amyloid beta, has raised considerable controversy in the wake of findings from two identical phase III studies, EMERGE and ENGAGE. The trials were terminated in March 2019 when a futility analysis determined aducanumab was unlikely to outperform placebo at completion. In October 201...

Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer's Disease - Vimarsana News

Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer's Disease

Published: Feb 22, 2021 AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences Inc., (Nasdaq: SAVA), a biotechnology company developing product candidates for Alzheimer’s disease, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for simufilam, its lead drug candidate for the treatment of Alzheimer’s disease. Official EOP2 meeting minutes indicate FDA and Cassava Sciences agree on key elements of a pivotal Phase 3 clinical program in support of a New Drug Application (NDA) filing for simufilam in A...

Biogen Alzheimer's drug puts FDA's judgment in harsh spotlight | Pine and Lakes Echo Journal - Vimarsana News

Biogen Alzheimer's drug puts FDA's judgment in harsh spotlight | Pine and Lakes Echo Journal

Biogen Alzheimer’s drug puts FDA’s judgment in harsh spotlight Biogen Inc. said Friday, Jan. 29, that the U.S. Food and Drug Administration is extending its review of aducanumab, an experimental therapy that patients and their families see as a potential lifeline. Written By: Anna Edney / Bloomberg News | 7:45 am, Feb. 2, 2021 × A sign for biotechnology company, Biogen, Inc., is seen on a building in Cambridge, Mass., on March 18, 2017. (Dominick/AFP/Getty Images/TNS) WASHINGTON (Tribune News Service) — A new drug for Alzheimer’s disease is on a tortuous path to...